Case-Based Clinical Approach: Multimodal Management of Cancer Pain in Small Animals

Cancer pain in veterinary patients is rarely singular in origin. It evolves with disease progression and often involves a combination of nociceptive, inflammatory, and neuropathic mechanisms. Translating theoretical knowledge into clinical practice requires a structured yet flexible approach. This case-based discussion illustrates how multimodal strategies can be effectively applied. 

Clinical Scenario 

A dog presents with osteosarcoma, showing progressive lameness, reduced activity, and decreased appetite. The pain is multifactorial, stemming from bone destruction, inflammation, and possible nerve involvement. 

Such cases highlight the complexity of oncologic pain, where multiple pathways contribute simultaneously. 

Initial Pain Assessment 

Accurate assessment is the first step. Behavioral indicators such as reluctance to move, posture changes, and reduced interaction should be evaluated alongside clinical findings². Pain scoring systems can help standardize evaluation and monitor response to therapy. 

Importantly, pain in cancer patients is dynamic and requires regular reassessment. 

Initiating Multimodal Analgesia 

Given the severity of pain, a multimodal approach is essential. This involves targeting different points along the pain pathway to achieve synergistic effects. 

Initial management may include: 

• Opioids (e.g., morphine or methadone) for strong analgesia  

• NSAIDs to control inflammation  

• Adjunct agents targeting central sensitization  

This combination enhances analgesic efficacy while allowing lower doses of individual drugs, reducing adverse effects¹. 

Opioid Selection and Optimization 

In this case, methadone is particularly useful due to its dual action as a µ-opioid agonist and NMDA receptor antagonist, making it effective for both nociceptive and neuropathic pain¹. 

As the patient stabilizes: 

• Transition to buprenorphine for sustained analgesia  

• Introduce tramadol as part of long-term management  

This stepwise approach ensures continuous pain control while minimizing risks associated with high-dose opioid use. 

Managing Central Sensitization 

Chronic cancer pain often leads to central sensitization, where the nervous system becomes hypersensitive^1,3,4,5. This results in exaggerated pain responses and reduced treatment efficacy if not addressed early. 

Preventive strategies include: 

• Consistent analgesia without gaps  

• Use of NMDA antagonists such as methadone  

• Early intervention before sensitization becomes established   

Perioperative Pain Management 

If surgical intervention is planned, the perioperative period requires careful analgesic planning. Surgical stress and inadequate pain control can suppress immune function and potentially influence tumor spread. 

A balanced approach may include: 

• Fentanyl infusion intraoperatively for rapid analgesia  

• Reduced opioid doses combined with adjunct techniques  

• Continuation of multimodal therapy postoperatively  

Such strategies help maintain analgesia while minimizing immunosuppressive effects¹. 

Long-Term Management and Monitoring 

Cancer pain management does not end after initial stabilization. As the disease progresses, therapy must be adjusted. 

Long-term considerations include: 

• Opioid rotation to prevent tolerance  

• Dose adjustments based on response  

• Monitoring for adverse effects  

Owner compliance is critical, particularly for at-home medication administration. Clear communication improves adherence and outcomes. 

Clinical Insights 

This case underscores several key principles: 

• Cancer pain is multifactorial and evolving  

• Multimodal analgesia provides superior outcomes  

• Opioid selection should be individualized  

• Continuous monitoring is essential for effective management   

Conclusion 

Effective cancer pain management in veterinary patients requires a balance between pharmacological knowledge and clinical judgment. A structured, multimodal approach allows veterinarians to address the complexity of oncologic pain while minimizing adverse effects. 

Ultimately, improving pain control directly enhances quality of life, reinforcing the central role of veterinarians in delivering compassionate, evidence-based oncology care. 

Reference 

1. Pinheiro AV, Petrucci GN, Dourado A, Silva F, Pires I. Pain Management in Animals with Oncological Disease: Opioids as Influencers of Immune and Tumor Cellular Balance. Cancers. 2024 Aug 29;16(17):3015. https://doi.org/10.3390/cancers16173015 

2. Reid J, Scott EM, Calvo G, Nolan AM. Definitive Glasgow acute pain scale for cats: validation and intervention level. Veterinary Record. 2017 May 6;108(18). https://eprints.gla.ac.uk/134522/1/134522.pdf 

3. Raja SN, Sivanesan E, Guan Y. Central sensitization, NMDA receptors, and human experimental pain models: bridging the gap between target discovery and drug development. Anesthesiology. 2019 Aug;131(2):233. https://pmc.ncbi.nlm.nih.gov/articles/PMC6640094/pdf/nihms-1527468.pdf 

4. Ma RS, Kayani K, Whyte-Oshodi D, Whyte-Oshodi A, Nachiappan N, Gnanarajah S, Mohammed R. Voltage gated sodium channels as therapeutic targets for chronic pain. Journal of pain research. 2019 Sep 9:2709-22. https://www.tandfonline.com/doi/pdf/10.2147/jpr.s207610 

5. Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. Journal of Applied Biobehavioral Research. 2018 Jun;23(2):e12137. https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jabr.12137